Business Context and Reporting Period
Company: Aquestive Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 10, 2026
Principal Executive Offices: Warren, NJ
This filing serves as a current report to disclose Regulation FD information and other material events. It includes the furnishing of an investor presentation and the announcement of clinical study results for the Company's lead product candidate.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This Form 8-K is focused on operational updates and regulatory disclosures rather than financial performance reporting.
Material Changes and Operational Updates
- Clinical Study Results: The Company announced results from a human factors validation study and a pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film.
- Regulatory Strategy: These studies were conducted to support the planned resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA).
- Indication: The product is intended for the treatment of Type 1 allergic reactions, including anaphylaxis.
- Investor Communications: The Company furnished an investor presentation to institutional investors and analysts, available via the Company's website.
Guidance, Outlook, and Risks
Outlook: Management is proceeding with the resubmission of the NDA for Anaphylm™ based on the positive study results announced in this filing.
Risks and Contingencies:
- The investor presentation and press release are furnished but not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability exposure for the information contained therein.
- The Company reserves the right to discontinue the availability of the investor presentation on its website at any time.
- Future regulatory approval is contingent upon the FDA's review of the resubmitted NDA.
Investor Verification Checklist
- Verify the specific data points and conclusions from the human factors validation and pharmacokinetic studies in the attached press release (Exhibit 99.1).
- Review the investor presentation (Exhibit 99.2) for updated timelines regarding the NDA resubmission and potential approval dates.
- Confirm the status of the NDA resubmission with the FDA once the filing is officially submitted.
- Monitor subsequent filings for any updates on the regulatory review process or changes to the development plan.